Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 11, 2022 07:20 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Completes Dosing in Altitude Trial

Topline data expected within two months Blinded, interim data to be presented at the Undersea & Hyperbaric Medical Society’s Annual Scientific Meeting in May 2022 CHARLOTTESVILLE, Va., April ...
April 08, 2022 07:20 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders

• Special Meeting of Stockholders Rescheduled to Monday, April 18, 2022 at 9:00 a.m. E.T.• No Change to Meeting Location, Record Date, or Proposals to Be Voted Upon CHARLOTTESVILLE, Va., April 08,...
March 21, 2022 07:20 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update

Altitude Trial Dosing Expected To Be Completed in 2Q2022; mid-2022 for ILD-DLCO TrialPhase 2 Hypoxic Solid Tumor Study Protocol Submission Planned to Support 2H22 Study Start$37.3M in Cash & Cash...
February 24, 2022 07:02 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts

CHARLOTTESVILLE, Va., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
December 20, 2021 07:02 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”

CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
December 16, 2021 08:59 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial

CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
December 01, 2021 07:02 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523

CHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
November 22, 2021 07:02 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Doses First Participants in Altitude Trial

CHARLOTTESVILLE, Va., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
November 10, 2021 07:02 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Announces Intent to Develop TSC to Treat Hypoxic TumorsAltitude Trial Expected to Commence in November 2021ILD-DLCO Trial Expected to Commence in Late December 2021 CHARLOTTESVILLE, Va., Nov. ...
October 28, 2021 07:30 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference

CHARLOTTESVILLE, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...